Skip to content

ADMA Biologics ADMA Debt-to-equity

Debt-to-equity at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
0.1×+0.1×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-0.5×
Zymeworks logo
ZymeworksZYME
0.1×0.0×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
0.1×-0.1×
Quest Diagnostics logo
Quest DiagnosticsDGX
0.9×-0.1×
Biohaven logo
BiohavenBHVN
2.2×+2.1×

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Current ratio+0.4×

Where this comes from

Calculated from ADMA Biologics’s reported figures.

Based on the most recent quarter.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's debt-to-equity?
ADMA Biologics (ADMA) reported debt-to-equity of 0.5× in Q1 2026.
How has ADMA Biologics's debt-to-equity changed year-over-year?
ADMA Biologics's debt-to-equity increased by 1961.8% year-over-year, from 0× to 0.5×.
What is the long-term trend for ADMA Biologics's debt-to-equity?
Over 5 years (2020 to 2025), ADMA Biologics's debt-to-equity has grown at a -31.5% compound annual growth rate (CAGR), from 1.1× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.